Journal
INTERNATIONAL IMMUNOPHARMACOLOGY
Volume 83, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.intimp.2020.106446
Keywords
Nanomedicine; Dendritic cell vaccine; Cancer immunotherapies
Categories
Funding
- National Institute for Medical Research Development (NIMAD) [976852]
- Iran National Science Foundation (INSF) [95849732]
- Tabriz University of Medical Sciences [59658]
- Student Research Committee of Tabriz University of Medical Sciences [58695]
Ask authors/readers for more resources
Dendritic cell (DC)-based cancer immunotherapy has shown impressive outcomes, including the development of the first FDA-approved anti-cancer vaccine. However, the clinical application of DC-based cancer immunotherapy is associated with various challenges. Promising novel tools for the administration of cancer vaccines has emerged from recent developments in nanoscale biomaterials. One current strategy to enhance targeted drug delivery, while minimizing drug-related toxicities, is the use of nanoparticles (NPs). These can be utilized for antigen delivery into DCs, which have been shown to provide potent T cell-stimulating effects. Therefore, NP delivery represents one promising approach for creating an effective and stable immune response without toxic side effects. The current review surveys cancer immunotherapy with particular attention toward NP-based delivery methods that target DCs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available